A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
Immunol Res
; 70(1): 129-133, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1504961
ABSTRACT
Azithromycin is a macrolide antibiotic. Recent evidence has demonstrated in vitro activity against a wide variety of respiratory tract viruses, including SARS-CoV-2 responsible for the current global pandemic COVID-19. A mechanism of action acting on different phases of the viral cycle is assumed. In addition to its in vitro antiviral properties, some evidence also suggests immunomodulatory and antifibrotic activity. These properties of azithromycin could be useful in the treatment of viral respiratory tract infections such as COVID-19. However, clinical data on the antiviral efficacy of azithromycin in the treatment of respiratory tract infections are inconsistent, both when used as monotherapy and in polypharmacological combination. In addition, cases of azithromycin-induced QT long and malignant arrhythmias are reported. In this short review, we attempt to determine the role of azithromycin in the treatment of viral respiratory tract infections such as COVID-19, therapeutic efficacy, or inefficacy?
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Azitromicina
/
SARS-CoV-2
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Immunol Res
Asunto de la revista:
Alergia e Inmunología
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
S12026-021-09244-x
Similares
MEDLINE
...
LILACS
LIS